Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers

被引：16

作者：

Russano, Marco ^{[1
]}

La Cava, Giulia ^{[1
]}

Cortellini, Alessio ^{[1
]}

Citarella, Fabrizio ^{[1
]}

Galletti, Alessandro ^{[2
]}

Di Fazio, Giuseppina Rita ^{[1
]}

Santo, Valentina ^{[1
]}

Brunetti, Leonardo ^{[1
]}

Vendittelli, Alessia ^{[1
]}

Fioroni, Iacopo ^{[1
]}

Pantano, Francesco ^{[1
]}

Tonini, Giuseppe ^{[1
]}

Vincenzi, Bruno ^{[1
]}

机构：

[1] Campus Biomed Univ Rome, Dept Med Oncol, Via Alvaro Portillo 21, I-00128 Rome, Italy

[2] San Camillo Forlanini Hosp, Div Med Oncol, I-00152 Rome, Italy

来源：

CURRENT ONCOLOGY | 2023年 / 30卷 / 02期

关键词：

immunotherapy; non-small cell lung cancer; immune checkpoint inhibitors; PD-1; PD-L1; antibodies; combination strategies; biomarkers; tissue biomarkers; liquid biopsy; IMMUNE CHECKPOINT INHIBITORS; PD-L1; EXPRESSION; NSCLC PATIENTS; OPEN-LABEL; CHEMOTHERAPY CHEMO; 1ST-LINE NIVOLUMAB; ADVERSE EVENTS; CHECKMATE; 9LA; PATIENTS PTS; PHASE-III;

D O I：

10.3390/curroncol30020181

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immunotherapy has revolutionized the treatment paradigm of non-small cell lung cancer and improved patients' prognosis. Immune checkpoint inhibitors have quickly become standard frontline treatment for metastatic non-oncogene addicted disease, either as a single agent or in combination strategies. However, only a few patients have long-term benefits, and most of them do not respond or develop progressive disease during treatment. Thus, the identification of reliable predictive and prognostic biomarkers remains crucial for patient selection and guiding therapeutic choices. In this review, we provide an overview of the current strategies, highlighting the main clinical challenges and novel potential biomarkers.

引用

页码：2366 / 2387

页数：22

共 178 条

[51] Classification of current anticancer immunotherapies [J].

Galluzzi, Lorenzo ;

Vacchelli, Erika ;

Bravo-San Pedro, Jose-Manuel ;

Buque, Aitziber ;

Senovilla, Laura ;

Baracco, Elisa Elena ;

Bloy, Norma ;

Castoldi, Francesca ;

Abastado, Jean-Pierre ;

Agostinis, Patrizia ;

Apte, Ron N. ;

Aranda, Fernando ;

Ayyoub, Maha ;

Beckhove, Philipp ;

Blay, Jean-Yves ;

Bracci, Laura ;

Caignard, Anne ;

Castelli, Chiara ;

Cavallo, Federica ;

Celis, Estaban ;

Cerundolo, Vincenzo ;

Clayton, Aled ;

Colombo, Mario P. ;

Coussens, Lisa ;

Dhodapkar, Madhav V. ;

Eggermont, Alexander M. ;

Fearon, Douglas T. ;

Fridman, Wolf H. ;

Fucikova, Jitka ;

Gabrilovich, Dmitry I. ;

Galon, Jerome ;

Garg, Abhishek ;

Ghiringhelli, Francois ;

Giaccone, Giuseppe ;

Gilboa, Eli ;

Gnjatic, Sacha ;

Hoos, Axel ;

Hosmalin, Anne ;

Jaeger, Dirk ;

Kalinski, Pawel ;

Kaerre, Klas ;

Kepp, Oliver ;

Kiessling, Rolf ;

Kirkwood, John M. ;

Klein, Eva ;

Knuth, Alexander ;

Lewis, Claire E. ;

Liblau, Roland ;

Lotze, Michael T. ;

Lugli, Enrico .

ONCOTARGET, 2014, 5 (24) :12472-12508

[52] Towards the introduction of the 'Immunoscore' in the classification of malignant tumours [J].

Galon, Jerome ;

Mlecnik, Bernhard ;

Bindea, Gabriela ;

Angell, Helen K. ;

Berger, Anne ;

Lagorce, Christine ;

Lugli, Alessandro ;

Zlobec, Inti ;

Hartmann, Arndt ;

Bifulco, Carlo ;

Nagtegaal, Iris D. ;

Palmqvist, Richard ;

Masucci, Giuseppe V. ;

Botti, Gerardo ;

Tatangelo, Fabiana ;

Delrio, Paolo ;

Maio, Michele ;

Laghi, Luigi ;

Grizzi, Fabio ;

Asslaber, Martin ;

D'Arrigo, Corrado ;

Vidal-Vanaclocha, Fernando ;

Zavadova, Eva ;

Chouchane, Lotfi ;

Ohashi, Pamela S. ;

Hafezi-Bakhtiari, Sara ;

Wouters, Bradly G. ;

Roehrl, Michael ;

Nguyen, Linh ;

Kawakami, Yutaka ;

Hazama, Shoichi ;

Okuno, Kiyotaka ;

Ogino, Shuji ;

Gibbs, Peter ;

Waring, Paul ;

Sato, Noriyuki ;

Torigoe, Toshihiko ;

Itoh, Kyogo ;

Patel, Prabhu S. ;

Shukla, Shilin N. ;

Wang, Yili ;

Kopetz, Scott ;

Sinicrope, Frank A. ;

Scripcariu, Viorel ;

Ascierto, Paolo A. ;

Marincola, Francesco M. ;

Fox, Bernard A. ;

Pages, Franck .

JOURNAL OF PATHOLOGY, 2014, 232 (02) :199-209

[53] The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials [J].

Galvano, A. ;

Gristina, V ;

Malapelle, U. ;

Pisapia, P. ;

Pepe, F. ;

Barraco, N. ;

Castiglia, M. ;

Perez, A. ;

Rolfo, C. ;

Troncone, G. ;

Russo, A. ;

Bazan, V .

ESMO OPEN, 2021, 6 (03)

[54] Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab [J].

Gandara, David R. ;

Paul, Sarah M. ;

Kowanetz, Marcin ;

Schleifman, Erica ;

Zou, Wei ;

Li, Yan ;

Rittmeyer, Achim ;

Fehrenbacher, Louis ;

Otto, Geoff ;

Malboeuf, Christine ;

Lieber, Daniel S. ;

Lipson, Doron ;

Silterra, Jacob ;

Amler, Lukas ;

Riehl, Todd ;

Cummings, Craig A. ;

Hegde, Priti S. ;

Sandler, Alan ;

Ballinger, Marcus ;

Fabrizio, David ;

Mok, Tony ;

Shames, David S. .

NATURE MEDICINE, 2018, 24 (09) :1441-+

[55] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[56] KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo (pbo) plus pem and platinum for metastatic nonsquamous NSCLC [J].

Garassino, M. C. ;

Gadgeel, S. M. ;

Speranza, G. ;

Felip, E. ;

Gonzalez, E. Esteban ;

Gomez, M. Domine ;

Hochmair, M. J. ;

Powell, S. F. ;

Bischoff, H. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Kurata, T. ;

Gray, J. E. ;

Schwarzenberger, P. O. ;

Jensen, E. ;

Abreu, D. Rodriguez .

ANNALS OF ONCOLOGY, 2022, 33 (07) :S992-S993

[57] Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors [J].

Gay, Francesca ;

D'Agostino, Mattia ;

Giaccone, Luisa ;

Genuardi, Mariella ;

Festuccia, Moreno ;

Boccadoro, Mario ;

Bruno, Benedetto .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (08) :471-478

[58] Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial [J].

Gogishvili, Miranda ;

Melkadze, Tamar ;

Makharadze, Tamta ;

Giorgadze, Davit ;

Dvorkin, Mikhail ;

Penkov, Konstantin ;

Laktionov, Konstantin ;

Nemsadze, Gia ;

Nechaeva, Marina ;

Rozhkova, Irina ;

Kalinka, Ewa ;

Gessner, Christian ;

Moreno-Jaime, Brizio ;

Passalacqua, Rodolfo ;

Li, Siyu ;

McGuire, Kristina ;

Kaul, Manika ;

Paccaly, Anne ;

Quek, Ruben G. W. ;

Gao, Bo ;

Seebach, Frank ;

Weinreich, David M. ;

Yancopoulos, George D. ;

Lowy, Israel ;

Gullo, Giuseppe ;

Rietschel, Petra .

NATURE MEDICINE, 2022, 28 (11) :2374-+

[59] Lung microbiota promotes tolerance to allergens in neonates via PD-L1 [J].

Gollwitzer, Eva S. ;

Saglani, Sejal ;

Trompette, Aurelien ;

Yadava, Koshika ;

Sherburn, Rebekah ;

McCoy, Kathy D. ;

Nicod, Laurent P. ;

Lloyd, Clare M. ;

Marsland, Benjamin J. .

NATURE MEDICINE, 2014, 20 (06) :642-647

[60] Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper [J].

Gomes, Fabio ;

Wong, Melisa ;

Battisti, Nicolo Matteo Luca ;

Kordbacheh, Tiana ;

Kiderlen, Mandy ;

Greystoke, Alastair ;

Luciani, Andrea .

BRITISH JOURNAL OF CANCER, 2020, 123 (06) :874-884

← 1 2 3 4 5 6 7 8 9 10 →